AI Precision Medicine Specialist Interview Questions

A strong answer distinguishes population-level stratification (precision) from individual-level customization (personalized), and explains how ML accelerates both.

Cover weighted sums of risk alleles from GWAS, linkage disequilibrium clumping, and how PRS is used for disease risk stratification.

Discuss coverage, cost, non-coding variant detection, and typical use cases for each technology.

Explain how OMOP standardizes heterogeneous EHR data across institutions, enabling federated analytics and reproducible ML.

Cover selection bias (unrepresentative cohorts), label bias (diagnostic disparities), and measurement bias (differential data quality across groups).

Discuss data ingestion (mutation, expression, methylation), feature engineering (pathway scores, embeddings), late vs. early fusion strategies, and validation against clinical endpoints.

Cover SMOTE/ADASYN, focal loss, stratified cross-validation, precision-recall trade-offs, and the importance of calibration in clinical settings.

Describe local training at each hospital, aggregation of model updates (not raw data), and how this addresses HIPAA/GDPR while enabling multi-site collaboration.

Cover the IMDRF risk matrix (seriousness of condition × significance of information provided by the software) and the four risk categories.

Discuss tokenization, BIO tagging schema, transformer-based models (e.g., PubMedBERT), annotation guidelines, and evaluation with F1 on entity-level spans.

Explain calibration curves, Brier score, and the clinical risk of overconfident predictions leading to inappropriate treatment decisions.

GWAS scans genetic variants for phenotype associations; PheWAS scans phenotypes for associations with a single variant. Both provide complementary evidence for biomarker discovery.

Discuss biomedical KG construction (genes, diseases, compounds, pathways), link prediction with graph neural networks, and validation through literature and wet-lab experiments.

Cover input distribution drift (PSI, KL divergence), prediction drift, outcome drift with lag, calibration monitoring, and alerting thresholds tied to clinical risk.

Discuss social vs. biological constructs of race, proxy variable risk, population stratification confounding, and the goal of equitable model performance without reinforcing disparities.

Cover RNA velocity, ATAC-seq tokenization, cross-attention between modalities, pre-training objectives (masked modality prediction), and downstream tasks like cell-type annotation and perturbation prediction.

Discuss CPIC Level A (gene-drug pairs with prescribing guidelines), annotation pipelines, alert logic, and clinician override mechanisms.

Cover propensity score matching, inverse probability weighting, doubly robust estimators, and the assumptions required (no unmeasured confounding, positivity, SUTVA).

Discuss LD score regression, principal component adjustment, ancestry-matched training, multi-ancestry meta-analysis methods (e.g., MR-MEGA), and portability limitations.

Explain molecular graph representations, patient-condition-drug heterogeneous graphs, message-passing schemes, and how genomic variants modulate interaction severity.

Cover multi-rater annotation strategies, learning from noisy labels (co-teaching, label smoothing), expert adjudication protocols, and confident learning methods.

Discuss local vs. global DP, privacy budget allocation across rounds, the trade-off between privacy guarantees and model utility for rare-variant detection, and secure aggregation.

Cover temporal alignment, sensor noise, data sovereignty, patient consent models, and the integration of time-series foundation models with static genomic risk profiles.

Discuss SHAP/LIME for post-hoc explanation, inherently interpretable models (EBMs, rule lists), counterfactual explanations, and FDA's guidance on Good Machine Learning Practice.

Cover structure-based variant annotation, stability prediction (ΔΔG), active site proximity analysis, and validation against ClinVar pathogenicity labels.

Cover clinical stakeholder alignment, IRB approval, data acquisition (tumor boards, sequencing lab), model development, prospective validation plan, CDSS integration, and post-deployment monitoring.

Discuss ancestry-stratified error analysis, root cause investigation (training data imbalance, LD structure differences), targeted data augmentation, and transparent reporting to stakeholders.

Cover external validation strategy, dataset shift detection, domain adaptation techniques, and honest communication about generalizability limitations.

Discuss error analysis on format-specific notes, annotation auditing, model fine-tuning on local data, fallback rule-based extraction, and establishing a feedback loop with clinical staff.

Cover transfer learning from large clinical corpora, few-shot and zero-shot techniques, synthetic data augmentation, literature-curated features, and collaboration with expert clinicians for phenotyping.

Discuss model explainability for the clinician, evidence presentation (pharmacogenomic guidelines, literature), clinical autonomy, documentation, and the principle that AI supports but does not replace clinical judgment.

Cover format standardization (FHIR/IEEE 11073), signal quality assessment, artifact detection, imputation strategies, and creating a robust ingestion pipeline with quality gates before model training.

Discuss MLflow/W&B experiment tracking, data versioning with DVC, model cards, reproducible pipeline definitions (Nextflow/Snakemake), and pre-submission documentation practices.

Cover inter-annotator agreement analysis, adjudication protocols, label harmonization through standardized ontologies (SNOMED-CT), and training with disagreement-aware loss functions.

Discuss ethical boundaries, the distinction between clinical decision support and utilization management, anti-discrimination laws, and the responsibility to advocate for patient welfare.

Cover document chunking strategy for abstracts, embedding model choice (PubMedBERT vs. OpenAI), vector store selection (Pinecone/Weaviate), retrieval ranking, and prompt template design for clinical queries.

Discuss dataset preparation (BC5CDR, GDA corpus), model architecture (token classification vs. span pair classification), fine-tuning strategy, and evaluation with precision/recall on relation triples.

Cover data storage (S3, Glacier), QC pipeline (PLINK), association testing (REGENIE/SAIGE on EC2/Spark), multiple testing correction (Bonferroni, FDR), and results visualization (Manhattan plots).

Discuss scheduled retraining triggers, data drift detection gates, automated regression testing against holdout clinical endpoints, model registry promotion stages, and blue-green deployment.

Cover federated averaging, secure aggregation, differential privacy noise injection, client selection strategies, and validation on a centralized held-out test set.

Discuss structured prompt templates, chain-of-verification (self-consistency checking), retrieval grounding against imaging findings, physician-in-the-loop review, and hallucination detection strategies.

Cover molecular graph construction (atoms as nodes, bonds as edges), 3D conformation encoding, pre-training on large molecular datasets (ZINC, ChEMBL), fine-tuning on binding affinity data (PDBbind), and virtual screening workflow.

Cover defining sensitive attributes, selecting fairness metrics (equalized odds, demographic parity), applying in-processing (adversarial debiasing) and post-processing (threshold adjustment) techniques, and reporting trade-offs.

Discuss rule definitions, conda environment management, cloud execution (AWS Batch), caching of intermediate results, and integration with a variant interpretation dashboard.

Cover embedding trial eligibility criteria and patient records into the same semantic space, hybrid search (dense + sparse filters for inclusion/exclusion criteria), and ranking by match confidence.

Look for evidence of empathy, use of analogies or visualizations, adjusting communication style based on audience, and confirming understanding through feedback.

Assess honesty, urgency of response, stakeholder communication, root cause analysis rigor, and the corrective actions taken including process improvements to prevent recurrence.

Look for concrete practices: following key conferences (NeurIPS health track, AMIA), reading journals (Nature Medicine, JAMIA), contributing to open-source projects, and engaging with communities.

Assess respect for domain expertise, ability to back up positions with evidence, willingness to compromise, and focus on shared goals (patient outcomes).

Look for concrete actions: initiating bias audits, pushing back on shortcuts, educating teammates, and balancing pragmatism with principles in regulated environments.